Lineage Cell Therapeutics Inc (AMEX:LCTX) does about 1.33M shares in volume on a normal day but saw 7333922 shares change hands in the recent trading day. The company now has a market cap of 170.15M USD. Its current market price is $0.75, marking an increase of 3.66% compared to the previous close of $0.72. The 52 week high reached by this stock is $1.15 whilst the lowest price level in 52 weeks is $0.37.
The consensus objective for the share price is $3.92, suggesting that the stock has a potential upside of 80.87% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 20, 2024 when Craig Hallum initiated the stock to “Buy” and issued a price target of $4. B. Riley Securities initiated its price target at $4.
The current price level is 22.73%, 46.02%, and 13.36% away from its SMA20, SMA50, and SMA200 respectively, with the LCTX price moving below the 50-day SMA on current market day. Lineage Cell Therapeutics Inc (LCTX) stock is up 9.90% over the week and 69.34% over the past month. Its price is 48.28% year-to-date and -23.97% over the past year.
To reach the target analysts have set, the stock logically needs to grow 80.87 percent from here.
Outstanding shares total 228.36M with insiders holding 0.42% of the shares and institutional holders owning 47.93% of the company’s common stock. The company has a return on investment of -20.23% and return on equity of -21.40%. The beta has a value of 1.53. Price to book ratio is 2.15 and price to sales ratio is 17.80.
